George A. Fisher Jr.
Clinical Trials
- Recruiting 3D Dynamic Contrast-Enhanced Ultrasound Imaging in Predicting Treatment Response in Patients With Liver Metastases From Colon Cancer
- Not Recruiting Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
- Not Recruiting Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
- Not Recruiting Combination SBRT (Stereotactic Body Radiotherapy) With TACE (Transarterial Chemoembolization) for Unresectable Hepatocellular Carcinoma
- Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
- Recruiting Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
- Not Recruiting Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
- Not Recruiting Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
- Not Recruiting Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
- Recruiting Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
- Recruiting Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
- Not Recruiting Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
- Recruiting Permission to Collect Blood Over Time for Research
- Not Recruiting An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
- Recruiting Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
- Recruiting Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
- Recruiting Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
- Not Recruiting Safety Study of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
- Recruiting Molecular Genetic and Pathological Studies of Anal Tumors
- Recruiting Immunotherapy Study for Surgically Resected Pancreatic Cancer
- Not Recruiting Evaluation of Stereotactic Radiosurgery For Liver Malignancies
- Not Recruiting AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
- Not Recruiting Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast
- Not Recruiting A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
- Not Recruiting Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
- Not Recruiting Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
- Not Recruiting A Study of Nilotinib Versus Imatinib in GIST Patients
- Not Recruiting An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed
- Not Recruiting A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma
- Not Recruiting Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
- Not Recruiting Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors
- Not Recruiting A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
- Not Recruiting PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
- Not Recruiting Phase II Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
- Not Recruiting Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer
- Not Recruiting Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
- Not Recruiting Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer
- Not Recruiting A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
- Not Recruiting Study of XL647 Administered Orally Daily to Patients With Solid Tumors
- Not Recruiting Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
- Not Recruiting A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
- Not Recruiting A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
- Not Recruiting High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
- Not Recruiting A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
- Not Recruiting An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
- Not Recruiting An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
- Not Recruiting S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
- Not Recruiting A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
- Not Recruiting Phase II Gemzar, Taxol & Avastin Combination as 1st Line Tx for Metastatic Breast CA
- Not Recruiting Study of GSK1363089 in Metastatic Gastric Cancer
- Not Recruiting A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer NSCLC.
- Not Recruiting Study of GDC-0973/XL518 in Patients With Solid Tumors
- Not Recruiting Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer
- Not Recruiting Phase 1 Trial of Oral Ixabepilone
- Not Recruiting A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
- Not Recruiting Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer
- Not Recruiting A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
- Not Recruiting Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project
- Not Recruiting Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases
- Not Recruiting Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
- Not Recruiting Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer
- Recruiting Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
- Recruiting Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
- Recruiting A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
- Recruiting Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
- Recruiting ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
- Recruiting Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Help
Trial Administration